title: Functional polymorphism of the NQO2 gene is associated with methamphetamine psychosis.
abstract: Several lines of evidence suggest that genetic factors contribute to the vulnerability of drug abuse such as methamphetamine (MAP), and that dopamine-quinones produced by administration of MAP may be involved in the mechanism of MAP-related symptoms. The detoxification of quinones is catalyzed by a family of proteins designated as quinone oxidoreductases (NQOs). We analysed the polymorphisms of NQO1 and NQO2 genes to elucidate the association with genetic vulnerability to MAP abuse in Japan. The genotype and allele frequencies for the polymorphism (Pro187Ser) of the NQO1 gene did not differ between each subgroup of patients and controls. In contrast, the genotype frequency for the insertion/deletion (I/D) polymorphism in the promoter region of the NQO2 gene was a significant (p = 0.038) difference between patients with prolonged-type MAP psychosis and controls. This study suggests that the NQO2 gene polymorphism contributes to the aetiology of MAP-related psychosis in Japanese.
authors.affiliation: Department of Psychiatry, Chiba University Graduate School of Medicine, Chiba, Japan.
authors.forename: Shintaro
authors.initials: S
authors.lastname: Ohgake
authors.forename: Kenji
authors.initials: K
authors.lastname: Hashimoto
authors.forename: Eiji
authors.initials: E
authors.lastname: Shimizu
authors.forename: Hiroki
authors.initials: H
authors.lastname: Koizumi
authors.forename: Naoe
authors.initials: N
authors.lastname: Okamura
authors.forename: Kaori
authors.initials: K
authors.lastname: Koike
authors.forename: Daisuke
authors.initials: D
authors.lastname: Matsuzawa
authors.forename: Yoshimoto
authors.initials: Y
authors.lastname: Sekine
authors.forename: Toshiya
authors.initials: T
authors.lastname: Inada
authors.forename: Norio
authors.initials: N
authors.lastname: Ozaki
authors.forename: Nakao
authors.initials: N
authors.lastname: Iwata
authors.forename: Mutsuo
authors.initials: M
authors.lastname: Harano
authors.forename: Tokutaro
authors.initials: T
authors.lastname: Komiyama
authors.forename: Mitsuhiko
authors.initials: M
authors.lastname: Yamada
authors.forename: Ichiro
authors.initials: I
authors.lastname: Sora
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Ujike
authors.forename: Yukihiko
authors.initials: Y
authors.lastname: Shirayama
authors.forename: Masaomi
authors.initials: M
authors.lastname: Iyo
mesh_terms: D000328:Adult; D000697:Central Nervous System Stimulants / Q000009:adverse effects*; D017931:DNA Primers; D005260:Female; D015870:Gene Expression; D005838:Genotype; D006801:Humans; D008297:Male; D008694:Methamphetamine / Q000009:adverse effects*; D017354:Point Mutation / Q000235:genetics; D011110:Polymorphism, Genetic / Q000235:genetics*; D011401:Promoter Regions, Genetic / Q000235:genetics; D011605:Psychoses, Substance-Induced / Q000209:etiology* / Q000235:genetics*; D011808:Quinone Reductases / Q000235:genetics*; D015183:Restriction Mapping
chemical_list: D000697:Central Nervous System Stimulants; D017931:DNA Primers; D008694:Methamphetamine; C419642:NRH - quinone oxidoreductase2; D011808:Quinone Reductases